FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983674089> ?p ?o ?g. }

• W1983674089 endingPage "788" @default.
• W1983674089 startingPage "781" @default.
• W1983674089 abstract "To assess the risks and benefits of erythropoietin versus erythrocyte transfusion in the treatment of the anemia of prematurity, we randomly assigned 19 anemic preterm infants (birth weight 988±227 gm; gestational age 27.6±1.2 weeks; age 41±15 days; all values mean ±SD) to receive either transfusion or subcutaneously administered erythropoletin (200 units/kg every other day for 10 doses). In the 10 erythropoietin recipients, corrected reticulocyte counts increased from 2%±1% to 7%±2% (p<0.001) and hematocrits increased from 27%±2% to 30%±4% (p<0.05). In the nine infants who underwent transfusion, reticulocyte counts did not increase, but hematocrits increased from 28%±4% to 41%±2% after initial transfusion (p<0.001) and had decreased to 34%±5% by day 20. Signs attributed to anemia (tachycardia, apnea with bradycardia, and poor weight gain) declined in both the erythropoietin recipients and those who underwent transfusion. However, five of nine infants who underwent transfusion had symptoms within 10 to 14 days and were given further transfusions. Marrow aspiration performed after 7 to 10 days of treatment showed that intants receiving erythropoietin had greater percentages of erythropoietic precursors (p<0.001), greater concentrations of mature erythroid progenitors (p<0.001), and higher cycling rates of erythroid progenitors (p<0.001). The percentage of mature stored neutrophils in marrow was lower in the erythropoietin group than in the transfusion group, resulting in an inverse myeloid/erythroid ratio (0.5:1 vs 6.2:1; p<0.001). After 20 days, absolute blood neutrophil counts were lower in the erythropoietin recipients (1.8±0.9×103 cells/μl) than in the infants who underwant transfusion (3.9±1.9×103 cells/μl; p<0.05). Administration of erythropoietin thus stimulated erythropoiesis and relieved signs attributed to anemia; the significance of the relative neutropenia remains to be determined. We conclude that erythropoietin administration offers promise as an alternative to erythrocyte transfusion in neonates with symptomatic anemia of prematurity. To assess the risks and benefits of erythropoietin versus erythrocyte transfusion in the treatment of the anemia of prematurity, we randomly assigned 19 anemic preterm infants (birth weight 988±227 gm; gestational age 27.6±1.2 weeks; age 41±15 days; all values mean ±SD) to receive either transfusion or subcutaneously administered erythropoletin (200 units/kg every other day for 10 doses). In the 10 erythropoietin recipients, corrected reticulocyte counts increased from 2%±1% to 7%±2% (p<0.001) and hematocrits increased from 27%±2% to 30%±4% (p<0.05). In the nine infants who underwent transfusion, reticulocyte counts did not increase, but hematocrits increased from 28%±4% to 41%±2% after initial transfusion (p<0.001) and had decreased to 34%±5% by day 20. Signs attributed to anemia (tachycardia, apnea with bradycardia, and poor weight gain) declined in both the erythropoietin recipients and those who underwent transfusion. However, five of nine infants who underwent transfusion had symptoms within 10 to 14 days and were given further transfusions. Marrow aspiration performed after 7 to 10 days of treatment showed that intants receiving erythropoietin had greater percentages of erythropoietic precursors (p<0.001), greater concentrations of mature erythroid progenitors (p<0.001), and higher cycling rates of erythroid progenitors (p<0.001). The percentage of mature stored neutrophils in marrow was lower in the erythropoietin group than in the transfusion group, resulting in an inverse myeloid/erythroid ratio (0.5:1 vs 6.2:1; p<0.001). After 20 days, absolute blood neutrophil counts were lower in the erythropoietin recipients (1.8±0.9×103 cells/μl) than in the infants who underwant transfusion (3.9±1.9×103 cells/μl; p<0.05). Administration of erythropoietin thus stimulated erythropoiesis and relieved signs attributed to anemia; the significance of the relative neutropenia remains to be determined. We conclude that erythropoietin administration offers promise as an alternative to erythrocyte transfusion in neonates with symptomatic anemia of prematurity." @default.
• W1983674089 created "2016-06-24" @default.
• W1983674089 creator A5026854749 @default.
• W1983674089 creator A5041051682 @default.
• W1983674089 date "1991-11-01" @default.
• W1983674089 modified "2023-10-18" @default.
• W1983674089 title "Recombinant erythropoietin compared with erythrocyte transfusion in the treatment of anemia of prematurity" @default.
• W1983674089 cites W103079393 @default.
• W1983674089 cites W115824884 @default.
• W1983674089 cites W1577514253 @default.
• W1983674089 cites W1680542063 @default.
• W1983674089 cites W1964615055 @default.
• W1983674089 cites W1984334072 @default.
• W1983674089 cites W1984943521 @default.
• W1983674089 cites W1988780361 @default.
• W1983674089 cites W1997559766 @default.
• W1983674089 cites W2019233486 @default.
• W1983674089 cites W2024983263 @default.
• W1983674089 cites W2026661918 @default.
• W1983674089 cites W2027424738 @default.
• W1983674089 cites W2029738096 @default.
• W1983674089 cites W2059599024 @default.
• W1983674089 cites W2063867610 @default.
• W1983674089 cites W2067143062 @default.
• W1983674089 cites W2078793923 @default.
• W1983674089 cites W2109524641 @default.
• W1983674089 cites W2148174441 @default.
• W1983674089 cites W2152493043 @default.
• W1983674089 cites W2154037033 @default.
• W1983674089 cites W2160906667 @default.
• W1983674089 cites W2177544070 @default.
• W1983674089 cites W2272907111 @default.
• W1983674089 cites W2312612422 @default.
• W1983674089 cites W2315613377 @default.
• W1983674089 cites W2430594017 @default.
• W1983674089 cites W3025393355 @default.
• W1983674089 cites W35258240 @default.
• W1983674089 cites W4205212536 @default.
• W1983674089 cites W4232595996 @default.
• W1983674089 cites W4249832396 @default.
• W1983674089 cites W4294360077 @default.
• W1983674089 doi "https://doi.org/10.1016/s0022-3476(05)80303-8" @default.
• W1983674089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1941387" @default.
• W1983674089 hasPublicationYear "1991" @default.
• W1983674089 type Work @default.
• W1983674089 sameAs 1983674089 @default.
• W1983674089 citedByCount "111" @default.
• W1983674089 countsByYear W19836740892012 @default.
• W1983674089 countsByYear W19836740892013 @default.
• W1983674089 countsByYear W19836740892014 @default.
• W1983674089 countsByYear W19836740892017 @default.
• W1983674089 countsByYear W19836740892019 @default.
• W1983674089 countsByYear W19836740892020 @default.
• W1983674089 countsByYear W19836740892021 @default.
• W1983674089 countsByYear W19836740892023 @default.
• W1983674089 crossrefType "journal-article" @default.
• W1983674089 hasAuthorship W1983674089A5026854749 @default.
• W1983674089 hasAuthorship W1983674089A5041051682 @default.
• W1983674089 hasConcept C104317684 @default.
• W1983674089 hasConcept C105580179 @default.
• W1983674089 hasConcept C126322002 @default.
• W1983674089 hasConcept C141071460 @default.
• W1983674089 hasConcept C185592680 @default.
• W1983674089 hasConcept C187212893 @default.
• W1983674089 hasConcept C2778248108 @default.
• W1983674089 hasConcept C2778376644 @default.
• W1983674089 hasConcept C2778403015 @default.
• W1983674089 hasConcept C2778534260 @default.
• W1983674089 hasConcept C2778917026 @default.
• W1983674089 hasConcept C2779234561 @default.
• W1983674089 hasConcept C2780014101 @default.
• W1983674089 hasConcept C42219234 @default.
• W1983674089 hasConcept C54355233 @default.
• W1983674089 hasConcept C55493867 @default.
• W1983674089 hasConcept C71924100 @default.
• W1983674089 hasConcept C86803240 @default.
• W1983674089 hasConcept C90924648 @default.
• W1983674089 hasConceptScore W1983674089C104317684 @default.
• W1983674089 hasConceptScore W1983674089C105580179 @default.
• W1983674089 hasConceptScore W1983674089C126322002 @default.
• W1983674089 hasConceptScore W1983674089C141071460 @default.
• W1983674089 hasConceptScore W1983674089C185592680 @default.
• W1983674089 hasConceptScore W1983674089C187212893 @default.
• W1983674089 hasConceptScore W1983674089C2778248108 @default.
• W1983674089 hasConceptScore W1983674089C2778376644 @default.
• W1983674089 hasConceptScore W1983674089C2778403015 @default.
• W1983674089 hasConceptScore W1983674089C2778534260 @default.
• W1983674089 hasConceptScore W1983674089C2778917026 @default.
• W1983674089 hasConceptScore W1983674089C2779234561 @default.
• W1983674089 hasConceptScore W1983674089C2780014101 @default.
• W1983674089 hasConceptScore W1983674089C42219234 @default.
• W1983674089 hasConceptScore W1983674089C54355233 @default.
• W1983674089 hasConceptScore W1983674089C55493867 @default.
• W1983674089 hasConceptScore W1983674089C71924100 @default.
• W1983674089 hasConceptScore W1983674089C86803240 @default.
• W1983674089 hasConceptScore W1983674089C90924648 @default.
• W1983674089 hasIssue "5" @default.
• W1983674089 hasLocation W19836740891 @default.

• next